==================================================================================
60. Quartile Q2. Impact factor = 3.0

Chasov V, Mukhametshin S, Gilyazova E, Davletshin D, Tikhomirova M, Topchu I, Valiullina A, Prete M, Bulatov E. // Emerging cell-based therapies for systemic sclerosis: From stem cells to CAR-T cells. // Current Issues in Molecular Biology. 2026 Jan 12;48(1):76.
DOI: 10.3390/cimb48010076

==================================================================================
59. Quartile Q1. Impact factor = 6.194

Khadiullina R, Chasov V, Gilyazova E, Davletshin D, Mirgayazova R, Mingaleeva R, Stephenson Clarke JR, Baud MG, Bulatov E. // Cellular activity upregulation of the thermolabile p53 cancer mutant Y220C by small molecule indazole derivatives. // Cell Death Discovery. 2025 Nov 7;11(1):508.
DOI: 10.1038/s41420-025-02781-6

​

Пресс-релизы:

1) Попасть в белки: «стражи генома» перепрограммируют организм на борьбу с опухолями (28.11.2025)
https://iz.ru/1997954/mariia-nediuk/popast-v-belki-strazhi-genoma-pereprogrammiruyut-organizm-na-borbu-s-opuholyami
2) Созданы молекулы, восстанавливающие активность противоопухолевого белка (01.12.2025) https://minobrnauki.gov.ru/press-center/news/nauka/99130/

==================================================================================
58. Quartile Q1. Impact factor = 3.9

Mukhametshin SA, Gilyazova EM, Davletshin DR, Ganeeva IA, Zmievskaya EA, Chasov VV, Petukhov AV, Valiullina AK, Spada S, Bulatov ER. // Allogeneic NKG2D CAR-T Cell Therapy: A Promising Approach for Treating Solid Tumors. // Biomedicines. 2025 Sep 22;13(9):2314.
DOI: 10.3390/biomedicines13092314

​

==================================================================================
57. Quartile Q2. Impact factor = 2.2

Zagidullin AA, Bulatov ER, Khrizanforov MN, Davletshin DR, Gilyazova EM, Strelkov IA, Miluykov VA. // Synthesis, biological and electrochemical evaluation of glycidyl esters of phosphorus acids as potential anticancer drugs. // Beilstein Journal of Organic Chemistry. 2025 Sep 15;21(1):1909-16.
DOI: 10.3762/bjoc.21.148

==================================================================================
​56. Quartile Q1. Impact factor = 5.9

Ershova A, Goldaeva A, Staliarova A, Bulatov E, Petukhov A, Barlev N. // Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology. // Frontiers in Immunology. 2025 Jul 14;16:1592377.
DOI: 10.3389/fimmu.2025.1592377

==================================================================================

55. Quartile Q2. Impact factor = 3.6

Ganeeva IA, Gilyazova EM, Khannanov AA, Nektorova ME, Rogov AM, Khaibullin TI, Zmievskaya EA, Bulatov ER. // Allogeneic Treg-derived artificial vesicles: A promising therapeutic modality for multiple sclerosis. // BioImpacts: BI. 2025 Aug 20;15:30880.
DOI: 10.34172/bi.30880

==================================================================================
54. Quartile Q4. Impact factor = 1.64

Mirgayazova R, Khadiullina R, Gilyazova E, Davletshin D, Ganeeva I, Zmievskaya E, Chasov V, Valiullina A, Bulatov E. // The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia. // Molecular Biology Research Communications. 2025;14(3):179.
DOI: 10.22099/mbrc.2025.51477.2054

==================================================================================
53. Quartile Q2. Impact factor = 2.5

Davidovich P, Nikolaev D, Khadiullina R, Gurzhiy V, Bulatov E. // Cyclic vinyl sulfones activate NRF2 to protect from oxidative stress-induced programmed necrosis. // Bioorganic & Medicinal Chemistry Letters. 2025 Mar 1;117:130058.
DOI: 10.1016/j.bmcl.2024.130058

Пресс-релизы:
1) https://minobrnauki.gov.ru/press-center/news/nauka/93208/
2) https://russian.rt.com/science/article/1413722-oksilitelnyi-stress-izobretenie-preparat

==================================================================================
52. Quartile Q1. Impact factor = 15.8

Ding M, Zong Q, Zhang D, Ullah I, Zhang X, Liang W, Li X, Bulatov E, Yuan Y. // Self-Adaptive Nanocarriers Overcome Multiple Physiological Barriers to Boosting Chemotherapy of Orthotopic Pancreatic Cancer. // ACS Nano. 2024 Dec 28.
DOI: 10.1021/acsnano.4c11514

==================================================================================
51. Quartile Q1. Impact factor = 5.4

Chasov V, Gilyazova E, Ganeeva I, Zmievskaya E, Davletshin D, Valiullina A, Bulatov E. // Gut Microbiota Modulation: A Novel Strategy for Rheumatoid Arthritis Therapy. // Biomolecules. 2024 Dec 23;14(12):1653.
DOI: 10.3390/biom14121653

==================================================================================
50. Quartile Q3.

Mirgayazova R, Khadiullina R, Filimonova M, Chasov V, Bulatov E. // Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer. // Exploration of Immunology. 2024 Dec 15;4(6):837-52.
DOI: 10.37349/ei.2024.00176

==================================================================================
49. Ядро РИНЦ (Российский журнал).

Филимонова М.Н., Хадиуллина Р.Р., Булатов Э.Р. // Возможности и перспективы применения экзогенных нуклеаз в терапии онкологических заболеваний // Российский онкологический журнал. - 2024. - Т. 29. - №2. - C. 116-129.
DOI: 10.17816/onco634753

==================================================================================
48. Quartile Q1. Impact factor = 6.0

Rakhmatullina AR, Zolotykh MA, Filina YV, Valiullina AK, Zmievskaya EA, Gafurbaeva DU, Sagdeeva AR, Bulatov ER, Rizvanov AA, Miftakhova RR. // Multicellular Cancer-Stroma Spheres (CSS) for In Vitro Assessment of CAR-T Cell-Associated Toxicity. // Cells. 2024 Nov 16;13(22):1892.
DOI: 10.3390/cells13221892

==================================================================================
47. Quartile Q1. Impact factor = 5.4

Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E. // Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells. // Cancer Immunology, Immunotherapy. 2024 Nov 2;74(1):3.
DOI: 10.1007/s00262-024-03817-z

==================================================================================
46. Quartile Q1. Impact factor = 6.0

Chasov V, Ganeeva I, Zmievskaya E, Davletshin D, Gilyazova E, Valiullina A, Bulatov E. // Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis. // Cells. 2024 Jul 30;13(15):1282.
DOI: 10.3390/cells13151282

==================================================================================
45. Quartile Q1. Impact factor = 9.627

Liu Y, Wang H, Ding M, Yao W, Wang K, Ullah I, Bulatov E, Yuan Y. // Ultrasound-Activated PROTAC Prodrugs Overcome Immunosuppression to Actuate Efficient Deep-Tissue Sono-Immunotherapy in Orthotopic Pancreatic Tumor Mouse Models. // Nano Letters. 2024 Jul 2;24(28):8741-51.
DOI: 10.1021/acs.nanolett.4c02287

==================================================================================
44. Quartile Q1. Impact factor = 4.5

Rakhmatullina AR, Zolotykh MA, Filina YV, Mingaleeva RN, Sagdeeva AR, Boulygina EA, Gafurbaeva DU, Bulatov ER, Rizvanov AA, Miftakhova RR. // Development of a novel prostate Cancer-Stroma Sphere (CSS) model for In Vitro tumor microenvironment studies. // Translational Oncology. 2024 Jun 1;44:101930.
DOI: 10.1016/j.tranon.2024.101930

==================================================================================
43. Quartile Q2. Impact factor = 2.2

Chasov V, Zmievskaya E, Ganeeva I, Gilyazova E, Davletshin D, Filimonova M, Valiullina A, Kudriaeva A, Bulatov E. // Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation. // Journal of Biomedical Research. 2024 May 31;38(6):531.
DOI: 10.7555/JBR.38.20240009

==================================================================================

42. Quartile Q2. Impact factor = 2.2

Chasov V, Davletshin D, Gilyazova E, Mirgayazova R, Kudriaeva A, Khadiullina R, Yuan Y, Bulatov E. // Anticancer therapeutic strategies for targeting mutant p53-Y220C. // Journal of Biomedical Research. 2024 May;38(3):222.
DOI: 10.7555/JBR.37.20230093

==================================================================================

41. Quartile Q1. Impact factor = 4.1

Zmievskaya EA, Mukhametshin SA, Ganeeva IA, Gilyazova EM, Siraeva ET, Kutyreva MP, Khannanov AA, Yuan Y, Bulatov ER. // Artificial Extracellular Vesicles Generated from T Cells Using Different Induction Techniques. // Biomedicines. 2024 Apr 20;12(4):919.
DOI: 10.3390/biomedicines12040919

==================================================================================
40. Quartile Q1. Impact factor = 5.7

Kaminskiy Y, Ganeeva I, Chasov V, Kudriaeva A, Bulatov E. // Asymmetric T-cell division: Insights from cutting-edge experimental techniques and implications for immunotherapy. // Frontiers in Immunology. 2024 Mar 1;15:1301378.
DOI: 10.3389/fimmu.2024.1301378

==================================================================================
39. Quartile Q1. Impact factor = 4.7

Chasov V, Zmievskaya E, Ganeeva I, Gilyazova E, Davletshin D, Khaliulin M, Kabwe E, Davidyuk YN, Valiullina A, Rizvanov A, Bulatov E. // Immunotherapy strategy for systemic autoimmune diseases: betting on CAR-T cells and antibodies.  // Antibodies. 2024 Feb 1;13(1):10.
DOI: 10.3390/antib13010010

==================================================================================
38. Quartile Q1. Impact factor = 6.1

Sultanaev V, Yakimova L, Nazarova A, Sedov I, Mostovaya O, Mukhametzyanov T, Davletshin D, Takuntseva D, Gilyazova E, Bulatov E, Stoikov I. // Pillar [5] arene/albumin biosupramolecular systems for simultaneous native protein preservation and encapsulation of a water-soluble substrate. // Journal of Materials Chemistry B. 2024;12(12):3103-14.
DOI: 10.1039/D3TB02961A

==================================================================================